754325
Last Update Posted: 2016-05-26
Recruiting has ended
All Genders accepted | 18 Years + |
100 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
The purpose of this study is to find out what effect the combination of fulvestrant (Faslodex) and dasatinib (Sprycel) has on advanced breast cancer compared to fulvestrant alone.
Eligibility
Relevant conditions:
Advanced Breast Cancer
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov